Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HDL-increasing effect of cyclofenil

B Persson, G Fex

    Acta Medica Scandinavica
    |January 1, 1980
    PubMed
    Summary

    Cyclofenil therapy significantly increased HDL cholesterol levels by 15% in patients with low high-density lipoprotein (HDL) cholesterol. This treatment showed a reversible increase in transaminases in some patients, indicating a favorable safety profile for managing HDL levels.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Decreased glomerular filtration rate in solderers exposed to cadmium.

    Occupational and environmental medicine·1995
    Same author

    Scalp blood lactate: a new test strip method for monitoring fetal wellbeing in labour.

    British journal of obstetrics and gynaecology·1995
    Same author

    Enzymuria in a population living near a cadmium battery plant.

    Occupational and environmental medicine·1995
    Same author

    Influence of body temperature on thyrotropic hormone release and lipolysis in the newborn infant.

    Acta paediatrica (Oslo, Norway : 1992)·1995
    Same author

    Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands.

    Journal of immunological methods·1995
    Same author

    Cancer incidence and mortality of patients with suspected solvent-related disorders.

    Scandinavian journal of work, environment & health·1995

    Area of Science:

    • Cardiology
    • Endocrinology
    • Pharmacology

    Background:

    • Low high-density lipoprotein (HDL) cholesterol is a significant risk factor for cardiovascular disease.
    • Current therapeutic options for increasing HDL levels are limited.
    • Apolipoprotein A-I (APO-AI) is a key component of HDL, and its levels reflect HDL functionality.

    Purpose of the Study:

    • To evaluate the efficacy of cyclofenil in increasing HDL levels in patients with low HDL.
    • To assess the safety and tolerability of cyclofenil therapy.

    Main Methods:

    • A cohort of nineteen patients with low HDL (measured by APO-AI) received cyclofenil as monotherapy.
    • Changes in HDL levels and liver transaminases were monitored throughout the study.

    Main Results:

    • Cyclofenil treatment resulted in a statistically significant increase of approximately 15% in HDL levels.
    • A mild, reversible elevation in transaminases was observed in 6 patients, without the need to discontinue therapy.

    Conclusions:

    • Cyclofenil is an effective therapeutic agent for significantly raising HDL cholesterol levels.
    • The drug demonstrates a favorable safety profile, with reversible side effects, making it a potential option for managing dyslipidemia.

    Related Experiment Videos